Sulfasalazine is recommended over methotrexate and leflunomide because it causes less immunosuppression
Evidence-Based Answer Compared with placebo, leflunomide improves clinical outcomes and delays radiologic progression of rheumatoid arthritis
Surveys suggest that although methotrexate (MTX) is the most commonly preferred first drug, 2 sulfasalazine (SSZ) remains the first choice among some
This study evaluates the efficacy and safety of leflunomide and sulfasalazine in rheumatoid
After the first year, it was 13
In both treatment groups, the most common reason for withdrawal during the treatment was adverse events
Don't let that aspect play on your mind too much
HAQ scores In resource-limited population, treatment with combination of methotrexate and sulphasalazine over a period of 6 months is equally efficacious in patients with active axSpA with and without peripheral arthritis, as evidenced by improved ASAS20 response rates, reduction in NSAID use and fewer patient
Other than glucocorticoids (steroids), DMARDs have been on the market the longest and have the most evidence to support their use
Sulfasalazine is a disease-modifying antirheumatic drug (DMARD) traditionally used in the treatment of inflammatory bowel diseases, rheumatoid arthritis and psoriatic arthritis
com
54% of reviewers reported a positive effect, while 23% reported a negative effect
3 out of 10 from a total of 679 ratings on Drugs
Methotrexate (-19, -7) <0
24 The Leflunomide
Leflunomide dose continued at 20 mg/day and the methotrexate dose could be increased to a maximum of 20 mg/week
Methotrexate, sulfasalazine, leflunomide and hydroxychloroquine are the commonly used DMARDs
Methods: An observational database of 1088 patients and 5141 patient years of DMARD treatment (2680 courses) from two academic hospitals was filtered for treatment
In those patients continuing therapy for a
Purpose: To compare the efficacy, safety, and cost-effectiveness of methotrexate (MTX) plus hydroxychloroquine (HCQ) vs MTX plus leflunomide (LEF) in established rheumatoid arthritis (RA) with inadequate response to MTX monotherapy in a real-world Chinese cohort
She suggested methotrexate as it seems to be the best
non-biological) DMARD that has been available for the treatment of rheumatoid arthritis since it was licensed by the FDA in 1998